Edition:
United States

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.50EUR
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
€1.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,332,041
52-wk High
€1.62
52-wk Low
€0.32

Chart for

About

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products... (more)

Overall

Beta: 0.22
Market Cap(Mil.): €867.94
Shares Outstanding(Mil.): 579.01
Dividend: --
Yield (%): --

Financials

  PHAR.AS Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -0.14 -- --
ROI: -78.15 -5.25 13.10
ROE: -234.14 -6.83 15.09

BRIEF-Pharming Enters Euronext Amsterdam SmallCap-Index (AScX)

* PHARMING ENTERS THE EURONEXT AMSTERDAM SMALLCAP-INDEX (ASCX) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 15 2018

BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3

* DELIVERED REVENUE FOR FULL YEAR OF EUR 89.6 MILLION (US$101.2 MILLION) - AN INCREASE OF 464% ON 2016

Mar 07 2018

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

Jan 17 2018

BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds

* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH

Jan 04 2018

Earnings vs. Estimates